Alterity Therapeutics Limited (ATHE)
ATHENASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.43
+0.0760 (+3.23%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $44.25m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.01 to $5.89
- Average volume
- 103.9k
- Previous close
- $2.35
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $13.67, +462.6% from here
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- Alterity Therapeutics Limited - Depositary Receipt Price Target Increased by 12.50% to $8.89Fintel · 1 day ago
- Alterity Therapeutics Limited Announces Revised Remuneration and Employment Terms for CEO Dr David StamlerFintel · Oct 21, 2026
- Alterity's ATH434 Demonstrates Slower MSA Progression In Phase 2 RTTNews · Oct 5, 2026
- Alterity Therapeutics Reports New ATH434 Data In MSA RTTNews · Oct 5, 2026
- Alterity To Initiate Phase 3 Trial Of ATH434 In MSA Subsequent To Receipt Of EOP2 Minutes From FDA RTTNews · Jul 7, 2026
- Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?Zacks · Jun 19, 2026
- Alterity Aligns With FDA On Phase 3 Design For ATH434 In Treating Multiple System Atrophy RTTNews · Jun 10, 2026
- Alterity Therapeutics Limited - Depositary Receipt (ATHE) Price Target Increased by 15.37% to 4.93Fintel · May 13, 2026
The company
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson's disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company's lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Australia and South Pacific
- Website
- alteritytherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.